Impact of molecular profiles in treatment outcome in prospective randomized trials
| Trial (reference) . | CR . | OR . | PFS . | OS . |
|---|---|---|---|---|
| CALGB 9712 (70) | None significant | None significant | IgVH, del 11q, del 17p | IgVH, del 11q, del 17p |
| ECOG 2997 (71) | None significant | None significant | IgVH (for FC only), del 11q, del 17p | Not stated |
| LRF CLL4 (59) | del 11q, del 17p | del 11q, del 17p | IgVH, del 11q, del 17p | Not stated |
| Trial (reference) . | CR . | OR . | PFS . | OS . |
|---|---|---|---|---|
| CALGB 9712 (70) | None significant | None significant | IgVH, del 11q, del 17p | IgVH, del 11q, del 17p |
| ECOG 2997 (71) | None significant | None significant | IgVH (for FC only), del 11q, del 17p | Not stated |
| LRF CLL4 (59) | del 11q, del 17p | del 11q, del 17p | IgVH, del 11q, del 17p | Not stated |
PFS indicates progression-free survival.